CROs/Service Providers

Biomedical Systems, Foundry Health partner for real-time data access

Tuesday, August 23, 2016

Biomedical Systems, a 40-year-old, family-owned, clinical trial provider to pharmaceutical, medical device, biotech and CROs, has announced a new partnership with digital health company Foundry Health of Chicago. The two companies will collaborate on the development of a proprietary cloud-based data management system that will allow sponsors immediate access to clinical trial data in real time.

[Read More]

Frenova Renal Research expands in the U.S.

Tuesday, August 23, 2016

Frenova Renal Research, a drug and medical device contract clinical development services provider dedicated to renal research, announced its opening of a new office location in downtown Durham, North Carolina, and the expansion of its U.S. field-based staff in New York, Illinois, North Carolina, Florida and Louisiana.

[Read More]

10 Tips for Enabling Better CRO-Sponsor Collaborations

Thursday, August 18, 2016

By Craig Morgan, brand development director at goBalto Inc.

By 2020[1] 72% of clinical trials are anticipated to be outsourced, up from just 23% in 2012. Sponsors are seeking cost reductions, access to specialized knowledge, and increased speed and agility. Meanwhile, CROs focus is on business goals related to economic outcomes for their owners, investors and shareholders. Each group is expecting deliverables and timelines to be met or exceeded for potentially different business reasons, leading to a traditional client/vendor-type relationship. Though alliances and partnerships are increasing, there continues to be a client/vendor mentality at the operational and management levels, which perpetuates a lack of trust and empowerment.

[Read More]

CROs Pharma Start, H2O Clinical to merge

Monday, August 15, 2016

H2O Clinical, based in Hunt Valley, Maryland and Northbrook, Illinois-based Pharma Start, have announced plans to merge. The CROs, which provide a range of outsourced research services to the pharmaceutical industry, already have a history of close collaboration. Each company will continue to operate as it has in the past, and there will be no disruption to current operations or customer contracts. 

[Read More]

Sekisui XenoTech expands hepatotoxicity testing

Monday, August 15, 2016

Sekisui XenoTech has added additional hepatotoxicity screening assays and methodologies to the company’s existing cytotoxicity contract research services. Cytotoxicity studies assess the risk that test articles may cause toxicity in cells, with hepatotoxicity specifically related to the liver.

[Read More]